Evidence map›Paper›PMID 26861136›Full record

ReviewInflammation2016

An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis.

Zahra Ahmadi, Gholamhossein Hassanshahi, Hossein Khorramdelazad, Nahid Zainodini, Leila Koochakzadeh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. A Non-Coding Oligonucleotide Recruits Cutaneous CD11bAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  7. The ability of biomarkers to assess the severity of atopic dermatitis.The journal of allergy and clinical immunology. Global · 2024
    Article
  8. Article
  9. Article
  10. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zahra AhmadiMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Gholamhossein HassanshahiMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Hossein KhorramdelazadMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Nahid ZainodiniMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Leila KoochakzadehDepartment of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran. L.koochakzadeh@yahoo.com.
Rafsanjan University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Investigations revealed substantial parts accomplished by chemokines specifically eotaxins and their specific receptors. They are functionally involved in the modulation of the pathologic state of tissue inflammation which is as a result of allergic reactions. Chemokines as small proteins with approximately 8-10 kDa molecular weight are considered and fit in the bigger family of cytokines, containing basic heparin-binding polypeptide mediators. Chemokines actively interfere in the processes of selective, oriented leukocyte (including eosinophil) recruitment. As eminent from their name, more specifically, eotaxins are specialized for eosinophils' oriented locomotion toward allergic inflamed regions. To date, three members are defined for eotaxin subfamily as follows: eotaxin-1 (CCL11), eotaxin-2 (CCL24), and eotaxin-3 (CCL26), all of them bind to and activate CCR3 but have a low level of homology and appear to exhibit different physiological potentials. Allergy is described as a clinical state in which a pathologic hypersensitivity reaction is always initiated throughout an immunologic mechanism; similar to other immunologic reactions, an allergic reaction could also either be antibody or cell mediated. This type of allergic reactions occurs in all age groups and damages several different organs, having a significant impact on the emotional and social health of patients and their families and relatives. Concerning introductory comments introduced above, the authors of the present review attempted to collect and provide the latest evidences and information regarding the correlation between expression of eotaxin family members and allergy, in a wider extent, in two important allergic disorders: atopic asthma (AA) and atopic dermatitis (AD). Overall, concerning the most recent articles published within the database in the life sciences literature regarding the fundamental role(s) played by eotaxins in the pathogenesis of AA and AD, the authors of the current article propose that eotaxins (CCL11, CCL24, and CCL26) play key role(s) during symptomatic inflammatory responses raised in response to allergic crisis of these two clinical states.

Indexed as

AsthmaChemokine CCL11Chemokine CCL24Chemokine CCL26ChemokinesChemokines, CCDermatitis, AtopicFood HypersensitivityHumansInflammationCCL11 protein, humanCCL24 protein, humanCCL26 protein, humanChemokine CCL11Chemokine CCL24Chemokine CCL26ChemokinesChemokines, CCallergic asthmaatopic dermatitischemokineeotaxin

Identifiers

PMID26861136
OpenAlexW2253379444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.